Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2015

Conditions
Central Serous Chorioretinopathy
Interventions
DRUG

Intravitreal Aflibercept injection

"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"

DRUG

Sham injection

"Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"

PROCEDURE

Half-fluence photodynamic therapy

"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"

Trial Locations (6)

138736

Asan medical center, Seoul

Unknown

Chungbuk national hospital, Chungju

Gangneung asan hospital, Gangneung

Seoul national university Bundang Hospital, Ilsan

Samsung seoul hospital, Seoul

150-034

Kim's Eye Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT01971190 - Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy | Biotech Hunter | Biotech Hunter